Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat
ObesityWeek 2025 (Nov 4–7, Atlanta) puts a major spotlight on non-incretin alternatives for obesity, with a special focus on treatments outside the widely discussed GLP-1 pathway134.
Currax Pharmaceuticals is presenting new data on CONTRAVE (naltrexone HCl/bupropion HCl), an oral, non-GLP-1 combination therapy, highlighting its efficacy for weight loss, appetite reduction, craving control, and sustained long-term outcomes4.
Multiple studies at ObesityWeek 2025 emphasize CONTRAVE’s differentiated profile, its effects on both biological and behavioral drivers of obesity, and its potential for cost savings in healthcare4.
Key presentations explore predictors of response, its dual effect on body weight and smoking cessation, outcomes in patients with depression or anxiety, changes in diet quality, and specific effects in varied subpopulations (e.g., by age, comorbidity, behavioral profile)4.
The conference marks a shift in obesity care strategy—pharmaceutical companies are expanding beyond incretin-based drugs, targeting not just weight loss but also broader cardiometabolic and mental health benefits3.
ObesityWeek 2025 is seen as the premier global meeting for new obesity science, with a multi-disciplinary approach, and is viewed as eclipsing previous diabetes and endocrinology conferences in importance for this field13.
Sources:
3. https://inizio.com/insights/leading-with-purpose-obesity-week-2025/
4. https://www.prnewswire.com/news-releases/currax-pharmaceuticals-to-spotlight-new-research-at-obesityweek-2025-highlighting-craving-control-behavioral-adherence-and-subpopulation-outcomes-with-contrave-302596289.html